Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

IDE397

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Ideaya Biosci

Drug class:

MAT2A inhibitor

Related drugs:

‹

›

MTAP deletion	Non Small Cell Lung Cancer	MTAP deletion	Non Small Cell Lung Cancer	IDE397 Sensitive: C2 – Inclusion Criteria IDE397 Sensitive : C2	IDE397 Sensitive: C2 – Inclusion Criteria IDE397 Sensitive : C2
MTAP deletion	Gastric Cancer	MTAP deletion	Gastric Cancer	IDE397 Sensitive: D – Preclinical IDE397 Sensitive : D	IDE397 Sensitive: D – Preclinical IDE397 Sensitive : D
MTAP deletion	Esophageal Cancer	MTAP deletion	Esophageal Cancer	IDE397 Sensitive: D – Preclinical IDE397 Sensitive : D	IDE397 Sensitive: D – Preclinical IDE397 Sensitive : D
MTAP deletion	Head and Neck Cancer	MTAP deletion	Head and Neck Cancer	IDE397 Sensitive: D – Preclinical IDE397 Sensitive : D	IDE397 Sensitive: D – Preclinical IDE397 Sensitive : D
MTAP deletion	Pancreatic Cancer	MTAP deletion	Pancreatic Cancer	IDE397 Sensitive: D – Preclinical IDE397 Sensitive : D	IDE397 Sensitive: D – Preclinical IDE397 Sensitive : D
MTAP deletion	Bladder Cancer	MTAP deletion	Bladder Cancer	IDE397 Sensitive: D – Preclinical IDE397 Sensitive : D	IDE397 Sensitive: D – Preclinical IDE397 Sensitive : D
MTAP deletion	Lung Adenocarcinoma	MTAP deletion	Lung Adenocarcinoma	IDE397 Sensitive: D – Preclinical IDE397 Sensitive : D	IDE397 Sensitive: D – Preclinical IDE397 Sensitive : D